GlobeNewsWire
13 Jul 2026, 13:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Sarepta Therapeutics is facing allegations that it failed to disclose significant safety risks and patient deaths related to acute liver failure associated with its gene therapy ELEVIDYS. — Severe safety concerns and patient deaths for a core product can lead to regulatory halts, restricted approvals, and massive loss of projected revenue.
-0.80A class action complaint alleges that Sarepta made materially false and misleading statements regarding the regulatory and commercial prospects of ELEVIDYS. — Allegations of securities fraud regarding a primary product pipeline can erode investor trust and trigger volatile sell-offs.
-0.40Law firm Johnson Fistel, PLLP is investigating potential breaches of fiduciary duty by Sarepta's officers and directors to seek corporate governance reforms and fund recovery. — Legal investigations into management's fiduciary duties create corporate instability and potential financial liabilities via settlements.
-0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Which stocks this story touches
The company is facing investigations for breaches of fiduciary duty and allegations of misleading statements regarding the safety of its gene therapy.
The company is being investigated by a law firm on behalf of investors who suffered losses.
The company is being investigated by a law firm for potential claims on behalf of long-term shareholders.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
